Ionara Bio

Company Overview

Snapshot

Founded in May 2024, Ionara Bio operates with 1–10 employees. The company has secured funding across two rounds from one investor, Peregrine Ventures, for a total of $800,000.

Business overview

Ionara Bio is a Health Tech & Life Sciences company focused on developing novel small molecules. The company's core technology targets and blocks the TRPV2 channel, which is a key driver of inflammatory responses, particularly those involving macrophages that impair cardiac structure and function following acute myocardial infarction (AMI). Ionara Bio's lead candidate is a first-in-class TRPV2 inhibitor designed to improve cardiac function and reduce pathological cardiac fibrosis, aiming to enhance post-AMI recovery. The company operates within the Pharma & Medical Biotechnology sector, with a focus on Biologicals and Molecules, serving the Healthcare & Life Sciences market.

Company Intelligence Q&A

What is Ionara Bio's primary focus?

Ionara Bio is developing novel, proprietary small molecules that target and block the TRPV2 channel, a key driver of inflammatory responses that impair cardiac structure and function following acute myocardial infarction (AMI).

When was Ionara Bio founded?

Ionara Bio was founded in May 2024.

What is the total capital raised by Ionara Bio?

Ionara Bio has raised a total of $800,000 across two funding rounds.

Which investor has participated in Ionara Bio's funding rounds?

Peregrine Ventures has participated in Ionara Bio's funding rounds, including a Seed round in January 2026.

What is the strategic goal of Ionara Bio's lead candidate?

Ionara Bio's lead candidate, a first-in-class TRPV2 inhibitor, is designed to improve cardiac function and reduce pathological cardiac fibrosis, ultimately leading to significantly enhanced post-AMI recovery.